I don't give a lot of meaning to the short interest figures reported every two weeks other than to look at trends and relative magnitude. It just doesn't make any sense to me that there should be a lot of shorting at penny levels...just the opposite.
Because I am not a trader, I wouldn't know what to do with L2 access. Regardless, I am much more interested in fundamentals.
If you can make sense as to why this company is selling at less than four bits a share when they have a product being sold in Europe and a reasonable chance for FDA approval in less than two years for a drug treating an indication (ED) that affects millions of men, I am all ears. I understand the disenchantment associated with the failure of Fispemifene, but it does seem to me that the current share price represents a significantly oversold condition. A high risk, of course. But high potential reward at these levels. But I thought that at a buck.
News 
Market Data 
Discover 
AI
